including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
The annual global premier event in nuclear medicine and molecular imaging, the 2026 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), has officially kicked off.
View moreDefence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
New approach could expand CAR T therapy from blood cancers to solid tumors
PET/MRI can reduce the need for biopsies in prostate cancer
Production problems hamper Lantheus bid for FDA approval of radiopharma dx kit
PET/CT guides treatment in men with recurrent prostate cancer
Ratio Therapeutics signs Ac-225 supply agreement with PanTera
